These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 24639026)

  • 1. [MUW researcher of the month].
    Mandorfer M
    Wien Klin Wochenschr; 2014 Mar; 126(5-6):184-5. PubMed ID: 24639026
    [No Abstract]   [Full Text] [Related]  

  • 2. [A triple combination therapy of simeprevir (SM), pegylated-interferon and ribavirin (PR) with chronic hepatitis C virus genotype 1 infection].
    Suzuki S; Kurosaki M; Izumi N
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():248-53. PubMed ID: 26845939
    [No Abstract]   [Full Text] [Related]  

  • 3. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
    Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
    Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 ΔG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients.
    Galmozzi E; Aghemo A
    J Clin Virol; 2014 Apr; 59(4):274-5. PubMed ID: 24495847
    [No Abstract]   [Full Text] [Related]  

  • 5. Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.
    Liu CH; Liang CC; Liu CJ; Tseng TC; Lin CL; Yang SS; Su TH; Lin JW; Chen JH; Chen PJ; Chen DS; Kao JH
    Antivir Ther; 2012; 17(6):1059-67. PubMed ID: 22898703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interferon in the treatment of viral hepatitis. The interferon was discovered 50 years ago].
    Fehér J; Lengyel G
    Orv Hetil; 2007 Aug; 148(33):1539-43. PubMed ID: 17686671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
    Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Pálinkás L; Berki T; Vincze A; Kisfali P; Melegh B
    Orv Hetil; 2013 Aug; 154(32):1261-8. PubMed ID: 23916907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of liver stiffness measurement by acoustic radiation force impulse (ARFI) among hepatitis C patients.
    Yamada R; Hiramatsu N; Oze T; Morishita N; Harada N; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Hayashi N; Takehara T
    J Med Virol; 2014 Feb; 86(2):241-7. PubMed ID: 24338811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C.
    Keshvari M; Pouryasin A; Behnava B; Sharafi H; Hajarizadeh B; Alavian SM
    Aliment Pharmacol Ther; 2014 Feb; 39(3):343. PubMed ID: 24397325
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.
    Boglione L; Cardellino CS; Cusato J; De Nicolò A; Cariti G; Di Perri G; D'Avolio A
    Infect Genet Evol; 2017 Jul; 51():167-172. PubMed ID: 28315743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?
    Di Marco V; D'Ambrosio R; Bronte F; Saracco G; Lanza AG; Forni G; Poggiali E; Calvaruso V;
    Dig Liver Dis; 2016 Jun; 48(6):650-5. PubMed ID: 27012446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Kinetics of Virus Load HCV-RNA in Blood Serum and Peripheral Mononuclear Cells in a Patient with Hepatocirrhosis and Chronic Virus Hepatitis C Termination Treated According to Noninterferon Treatment Scheme (Cycloferon + Ribavirin)].
    Stelmah VV; Kozlov VK; Nekrasova AN
    Antibiot Khimioter; 2015; 60(3-4):24-30. PubMed ID: 26415380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Letter: the rs12979860 and ss469415590 polymorphisms of IFNL4 gene are in strong linkage disequilibrium in Caucasian patients with chronic hepatitis C--authors' reply.
    Stättermayer AF; Ferenci P
    Aliment Pharmacol Ther; 2014 Feb; 39(3):344. PubMed ID: 24397327
    [No Abstract]   [Full Text] [Related]  

  • 14. Pathophysiology and clinical application of the renin system: early steps toward personalized medicine.
    Bühler FR
    Am J Hypertens; 2014 Aug; 27(8):996-9. PubMed ID: 25103927
    [No Abstract]   [Full Text] [Related]  

  • 15. Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study.
    Imazeki F; Yokosuka O; Omata M
    Expert Rev Anti Infect Ther; 2010 May; 8(5):497-9. PubMed ID: 20455677
    [No Abstract]   [Full Text] [Related]  

  • 16. Is antiviral treatment (IFN alpha and/or ribavirin) justified in cirrhosis related to hepatitis C virus? Société Royale Belge de Gastro-entérologie.
    Poynard T; Moussalli J; Ratziu V; Thevenot T; Regimbeau C; Opolon P; Horsmans Y; Brenard R; Closon M; Fevery J; Hautekeete M
    Acta Gastroenterol Belg; 1998; 61(4):431-7. PubMed ID: 9923094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of fibrosis during HCV recurrence after liver transplantation--influence of IL-28B SNP and response to peg-IFN and ribavirin treatment.
    Ackefors M; Nyström J; Wernerson A; Gjertsen H; Sönnerborg A; Weiland O
    J Viral Hepat; 2013 Nov; 20(11):770-8. PubMed ID: 24168256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired response to interferon-alpha2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection.
    Aghemo A; Rumi MG; Soffredini R; D'Ambrosio R; Ronchi G; Del Ninno E; Gallus S; Colombo M
    Antivir Ther; 2006; 11(6):797-802. PubMed ID: 17310824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of hepatitis C virus-related cirrhosis].
    Bronowicki JP
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B220-4. PubMed ID: 12180292
    [No Abstract]   [Full Text] [Related]  

  • 20. MUW researcher of the month November 2016.
    Wien Klin Wochenschr; 2016 Dec; 128(23-24):928-929. PubMed ID: 27878612
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.